Surrozen, Inc.
NASDAQ:SRZNBiotechnology
-$1.14 today
- Market cap
- $237.33M
- Beta
- 0.51
- P/E (TTM)
- -0.7
- EPS (TTM)
- -$31.29
Volume 0.31M
Average 0.11M
SRZN Cash & Equivalents
Cash on hand and highly liquid investments that can be converted to cash almost immediately.
Surrozen, Inc.NASDAQ: SRZN
Cash & Equivalents · Q1 FY2026 · quarter ended Mar 2026
Cash & equivalents rises 5.2% from a year ago
Cash & equivalents stood at $106.91M at the end of Q1 FY2026, up 5.2% from a year earlier and up 19.8% from the prior quarter. Over 3 fiscal years it compounded at +53.5% a year.
Context
- Cash & equivalents amounted to 88.6% of total assets at the end of Q1 FY2026, unchanged from a year earlier.
- Cash & equivalents increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether cash & equivalents keeps rising in the next quarterly balance sheet after a +5.2% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Cash & Equivalents history
USD · from the balance sheet
- Latest · FY2025
- 89.25M USD
- Year-over-year change
- +158.2%
- 4-year CAGR
- +28.1%
| Period | Period end | Cash & Equivalents | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 89.25M | +158.2% |
| FY2024 | 2024-12-31 | 34.57M | -4.1% |
| FY2023 | 2023-12-31 | 36.04M | +46.0% |
| FY2022 | 2022-12-31 | 24.69M | -25.4% |
| FY2021 | 2021-12-31 | 33.09M | — |
Cash & Equivalents vs competitors
How SRZN compares with its peers on the latest reported figures
- SRZN's Mar 2026 cash & equivalents of $106.91M is the highest of the 8 companies compared; the peer median is $35M.
- Its year-over-year change of +5.2% is the 6th highest of 8, against a peer median of +89.3%.
- Cash & equivalents amounts to 88.6% of total assets for SRZN, versus a peer median of 82.7%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $106.91M | +5.2% | +53.5% | 88.6% | |
| Mar 2026 | $79.25M | +397.8% | +91.2% | 82.7% | |
IRDOpus Genetics, Inc. | Mar 2026 | $59.96M | +43.5% | +1.9% | 89.8% |
| Mar 2026 | $47.32M | -9.8% | -3.9% | 17.4% | |
| Mar 2026 | $35M | +89.3% | -74.4% | 18.8% | |
| Mar 2026 | $31.13M | +89.5% | -4.0% | 86.1% | |
| Mar 2026 | $10.51M | +282.0% | — | 100.0% | |
| Mar 2026 | $5.02M | -67.3% | -46.7% | 2.5% | |
| Peer median (excluding SRZN) | $35M | +89.3% | -3.9% | 82.7% | |
Competitors are the stored peer set for SRZN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 33.09M | 24.69M | 36.04M | 34.57M | 89.25M |
| Short-term Investments | 68.76M | 51.15M | 0 | 0 | 0 |
| Net Receivables | 0 | 1.98M | 2.15M | 2.54M | 208K |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Other Current Assets | 0 | 756K | 580K | 671K | 2.11M |
| Total Current Assets | 105.19M | 81.31M | 41.13M | 38.93M | 91.56M |
| Property, Plant & Equipment (Net) | 9.38M | 6.9M | 3.86M | 8.36M | 6.43M |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 |
| Long-term Investments | 21.66M | 0 | 688K | 0 | 688K |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 954K | 1.23M | 402K | 1.17M | 46K |
| Total Non-current Assets | 31.99M | 8.13M | 4.95M | 9.54M | 7.17M |
| Total Assets | 137.17M | 89.44M | 46.08M | 48.47M | 98.73M |
| Account Payables | 2.72M | 658K | 525K | 306K | 728K |
| Short-term Debt | 0 | 0 | 0 | 0 | 0 |
| Tax Payables | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 589K | 581K | 292K | 191K | 289K |
| Total Current Liabilities | 13.57M | 9.73M | 7.15M | 7.32M | 9.93M |
| Long-term Debt | 0 | 0 | 0 | 0 | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Liabilities | 8.3M | 326K | 115K | 55.89M | 271.21M |
| Total Non-current Liabilities | 13.9M | 3.7M | 997K | 62.53M | 276.56M |
| Total Liabilities | 27.47M | 13.43M | 8.15M | 69.85M | 286.49M |
| Common Stock | 4K | 0 | 0 | 0 | 1K |
| Retained Earnings | (142.65M) | (178.65M) | (221.7M) | (285.26M) | (527.29M) |
| Accumulated OCI | (119K) | (241K) | 0 | 0 | 0 |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 109.7M | 76M | 37.94M | (21.38M) | (187.76M) |
| Total Debt | 7.79M | 5.6M | 3.38M | 8.47M | 6.64M |
| Net Debt | (25.3M) | (19.09M) | (32.66M) | (26.1M) | (82.61M) |
Surrozen, Inc.
NASDAQ:SRZN
Intrinsic Alpha fair value
Locked
Current Price
$31.74
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.